Therapeutic targeting of MYC- and MYCN-driven medulloblastoma with a novel MYC degrader molecule
This study demonstrates that UNSW-SC-22, a novel brain-penetrant MYC/MYCN degrader, effectively suppresses tumor growth and prolongs survival in preclinical models of aggressive medulloblastoma, either as a monotherapy or in combination with HDAC inhibitors.
Original paper dedicated to the public domain under CC0 1.0 (https://creativecommons.org/publicdomain/zero/1.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Imagine your brain is a bustling city, and sometimes, a tiny, rebellious gang called Medulloblastoma takes over the most dangerous neighborhoods. This gang is led by two notorious bosses: MYC and MYCN. These bosses are like chaotic construction foremen who won't stop ordering new buildings (cells) to be built, causing the city to spiral out of control.
For a long time, doctors have struggled to catch these bosses because they are "shape-shifters." Unlike a solid, predictable villain, MYC and MYCN are floppy and disorganized, making it nearly impossible to build a key (a drug) that fits their lock. Most drugs that work on other cancers can't even get into the city because of a super-tight security fence called the Blood-Brain Barrier (BBB). It's like a bouncer who only lets in specific VIPs, and unfortunately, most cancer drugs get turned away at the door.
But now, a team of scientists has built a brand-new, sneaky tool called UNSW-SC-22. Here is how it works, based on their latest findings:
The New Weapon: A Degrader, Not Just a Blocker
Instead of trying to freeze the bosses in place, UNSW-SC-22 is a "degrader." Think of it like a specialized demolition crew. When this molecule finds MYC or MYCN, it doesn't just sit there; it latches onto them and tags them for immediate destruction. It's like the molecule whispers to the cell's internal trash compactor (the proteasome), saying, "Hey, get rid of this guy right now!"
The scientists found that UNSW-SC-22 directly binds to the MYC protein. They measured this connection and found it holds on with an affinity (a measure of how tight the grip is) of 12.5 ± 3.0 µM. It's a firm handshake, not a high-five. Once it grabs on, it speeds up the trash compactor, reducing the lifespan of the MYC protein by 40%.
The "Shape-Shifter" Problem is Solved (Sort Of)
The paper explicitly argues against the idea that you need to stop the instructions (the mRNA) to stop the bosses. The scientists checked the instructions and found they were still being written. The magic of UNSW-SC-22 is that it destroys the bosses themselves after they are built, regardless of how many instructions are being printed.
They tested this by turning off the MYC instructions in a lab setting. When the instructions were gone, the drug stopped working. This proves the drug needs the boss to be there to work its magic. It's not a general poison; it's a targeted hit.
Getting Past the Bouncer
The most exciting part? This molecule is a VIP. The scientists tested it in mice and found it could cross the Blood-Brain Barrier. In fact, it was so good at getting in that the concentration in the brain was actually 1.44 times higher than in the blood at its peak. It's like the molecule didn't just sneak past the bouncer; it convinced the bouncer to open the gate and let it in.
The Results: Slowing the Chaos
When they tested UNSW-SC-22 on brain tumor cells in a dish:
- It killed the high-MYC cells very effectively, with a dose needed to kill half the cells (IC50) ranging from 0.22 to 1.18 µM.
- It was much safer for normal cells. The normal cells needed doses 2.18 to over 10 µM to be affected, meaning the drug is picky and prefers the bad guys.
- It stopped the cells from dividing, caused them to self-destruct (apoptosis), and even damaged their DNA, making it impossible for them to recover.
The Power-Up Combo
The scientists also tried a "tag-team" strategy. They knew that another type of drug, called an HDAC inhibitor (specifically one named entinostat), helps loosen the bosses' grip on the cell. When they combined UNSW-SC-22 with entinostat, the effect was even stronger. It was like having the demolition crew work while the security system was temporarily disabled. This combo reduced the bosses even more and caused more cell death than either drug alone.
What Happened in the Mouse City?
The researchers took this to the next level by testing it in mice with human brain tumors.
- In MYC-driven tumors: The drug crossed the barrier and slowed down the tumor growth. The mice lived longer, though the improvement in total survival time was small (about 2 days longer on average), suggesting the tumors were very aggressive and the treatment window was short.
- In MYCN-driven tumors: This is where the combo really shined. In mice with tumors driven by the MYCN boss, the combination of UNSW-SC-22 and entinostat significantly prolonged their lives compared to mice that got no treatment or just one drug.
The Bottom Line
The paper suggests that UNSW-SC-22 is a promising new tool. It's not a magic cure-all that has "solved" medulloblastoma yet. The researchers are careful to say this is a "preclinical" study, meaning it's been tested in cells and mice, but not yet in humans. However, it proves that it is possible to build a drug that directly targets these floppy, "undruggable" bosses, crosses the brain's security fence, and works best when teamed up with other helpers.
The scientists are now suggesting that this approach—degrading the boss rather than just blocking it—could be a major step forward for treating these high-risk brain tumors, especially if we can keep refining the drug and the team-up strategies.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.